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ABSTRACT
Although p53 and p73 share considerable homology
in their DNA-binding domains, there have been few
studies examining their relative interactions with
DNA as purified proteins. Comparing p53 and p73b
proteins, our data show that zinc chelation by EDTA
is significantly more detrimental to the ability of
p73b than of p53 to bind DNA, most likely due to the
greater effect that the loss of zinc has on the con-
formation of the DNA-binding domain of p73.
Furthermore, prebinding to DNA strongly protects
p73b but not p53 from chelation by EDTA suggest-
ing that DNA renders the core domain of p73 less
accessible to its environment. Further exploring
these biochemical differences, a five-base sub-
sequence was identified in the p53 consensus
binding site that confers a greater DNA-binding
stability on p73b than on full-length p53 in vitro.
Surprisingly, p53 lacking its C-terminal non-specific
DNA-binding domain (p53D30) demonstrates the
same sequence discrimination as does p73b. In
vivo, both p53 and p73b exhibit higher transactiva-
tion of a reporter with a binding site containing this
sub-sequence, suggesting that lower in vitro disso-
ciation translates to higher in vivo transactivation of
sub-sequence-containing sites.
INTRODUCTION
The p53 gene family consists of the well studied tumor sup-
pressor p53, as well as p73 and p63 (1–3). All three share
signiﬁcant sequence homology and can act as transcription
factors initiating cell-cycle arrest or apoptosis under certain
conditions. The three proteins are thought to have evolved
from a common ancestor, possibly similar to the Caenorhab-
ditis elegans p53 ortholog CEP-1 (4–6), with p53 being the
most recently evolved family member (3). Each p53 family
gene can be expressed as multiple isoforms generated both
by differential promoter usage and alternative splicing (7,8).
The p53 protein is organized into several functional
domains (9). The N-terminal region (amino acids 1–100)
contains two transactivation sub-domains (amino acids 20–
40 and 40–60) followed by a proline-rich region (amino
acids 60–90) that plays a selective role in transactivation
and apoptosis. The central region comprising a protease-
resistant core domain (amino acids 100–300) has sequence-
speciﬁc DNA-binding activity and sustains the vast majority
of missense mutations that occur in many forms of human
cancer. The core domain is joined to the tetramerization
domain (amino acids 325–355) by a 25 amino acid linker
region that contains a nuclear localization signal. Finally, at
the extreme C-terminus is a highly basic region (amino
acids 363–393) which can associate in a non-sequence depen-
dent manner with various forms of both DNA and RNA. The
transactivation and tetramerization domains and, to a much
greater extent, the sequence-speciﬁc DNA-binding domain
are conserved between the p53 family members. There is
no region within any of the known p73 and p63 isoforms,
however, that resembles the p53 basic C-terminus.
Interaction with DNA is crucial to the role of p53 as a tran-
scription factor. The consensus sequence bound by p53 con-
tains two PuPuPuCWWGPyPyPy 10 bp half-sites separated
by 0–13 bases (10). Following induction by DNA-damaging
agents, hypoxia and other stresses, p53 binds DNA as a tetra-
mer; the two dimers each bind to one 10mer of the bipartite
consensus sequence (11–14). Recent analyses derived from
crystal structures show that each p53 dimer is then further
stabilized on DNA by protein–protein interactions (15,16).
In vivo, an exact p53 consensus site is rarely found (17)
and p53 can tolerate some variation in its binding site, both
in sequence and, to a lesser extent, spacing between the 10
base half-sites. The bases within the CWWG component of
the consensus sequence, however, are the least frequently
changed in vivo. p53 does exhibit a difference in binding
afﬁnity and transactivation of different target gene promoters
in vivo, most interestingly between pro-apoptotic and non-
apoptotic genes (18–21). Furthermore, frequencies of
nucleotides found at each position in known p53-binding
sites have been assessed, but the correlation between
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promoters is still unclear (22–24).
Proper conformation of the p53 core DNA-binding domain
is necessary for DNA binding and transactivation of target
genes. Many p53 tumor derived mutations within the core
disrupt the domain conformation and diminish or abrogate
sequence-speciﬁc DNA binding (25). The p53 core domain
structure consists of a beta sandwich that supports two
large loops and a loop–sheet–helix motif (26,27). Loops
2 and 3 are held together in part by a zinc atom, and, together
with the loop–sheet–helix motif, form the DNA-binding
surface of p53. Three cysteines (Cys176, Cys238 and
Cys242) and one histidine (His179) in the DNA-binding
domain of p53 coordinate one molecule of zinc (26). Zinc
coordination is necessary for proper folding of the p53 core
domain in vitro and in cultured mammalian cells and disrup-
tion of this interaction greatly reduces or abrogates p53 DNA
binding and transactivation of target genes (28–30).
Understanding the role(s) of the second sequence-non-
speciﬁc DNA-interacting domain of p53 located in its
extreme C-terminus has been challenging. Biochemical
experiments using long oligonucleotides or circular DNA
indicate that the C-terminus is a positive regulator of p53
sequence-speciﬁc DNA binding, presumably by allowing
p53 to locate speciﬁc binding sites more efﬁciently (31,32).
Further, this region confers on p53 the ability to diffuse lin-
early along DNA (31). On short oligonucleotides, however,
experiments indicate that the C-terminus negatively regulates
DNA binding, a phenomenon possibly explained by its rapid
diffusion from the ends of the short DNA which would
increases the dissociation rate of p53 (33).
p73 was ﬁrst identiﬁed by Kaghad et al. (34) and Jost et al.
(35) in 1997. Since then, much has been discovered about
this protein but many questions still remain unanswered
(3,36–40). The p73 gene contains 14 exons, which, through
splicing, can produce at least six TA full-length isoforms
that differ in their C-terminus (generated by alternative splic-
ing) and the corresponding DN isoforms (generated by
transcription from an internal promoter). The domain organ-
ization of the p73 protein is similar to that of p53: the TA
isoforms contain an N-terminal transactivation domain
(20–30% homology to p53), a core DNA-binding domain
(65% homology), and a tetramerization domain (35–45%
homology). The DN isoforms of p73 lack the transactivation
domain and are thought to act in a dominant-negative fashion,
both for TAp73 and p53 (41–43) although in at least one
setting they can display the ability to activate transcription
(44). In vivo, p73a and b are the most commonly found
forms, both in the TA and DN variety. Of these, p73b has
a higher afﬁnity for DNA in vitro, and TAp73b is the most
potent isoform for transactivation and induction of growth
suppression and apoptosis (2,3,36,45–47). Like p53, p73 is
presumed to bind DNA as a tetramer, and its different
isoforms can form heterotetramers, allowing for another
level of regulation (48,49).
p73 has been shown to transactivate a number of p53 target
genes, and induce cell-cycle arrest and apoptosis (1). Interest-
ingly, while p73 and p53 have a number target genes in com-
mon, p73 also exhibits promoter selectivity and has a number
of unique target genes that are distinct from p53 (50–53).
Unlike p53, p73-mediated apoptosis does not require its
extreme C-terminal domain and deleting the p73 C-terminus
does not affect the in vivo or in vitro DNA-binding activities
of the protein (31,45,47,54).
While p53 structure and its interaction with DNA have
been explored in great detail, little is known about p73 in
this regard and very few papers have reported results on the
DNA-binding properties of puriﬁed p73 proteins. In this
work, we have determined a puriﬁcation strategy for produc-
ing active p73b and characterized similarities and differences
between p53 and p73b in their interaction with DNA.
MATERIALS AND METHODS
Tissue culture and antibodies
SF9 cells used for production of proteins expressed from
recombinant baculoviruses were grown in TC100 medium,
supplemented with 10% FBS. H1299 human lung epithelial
cells (p53 null) were grown in DME medium supplemented
with 10% FBS. H1299 cells that express tetracycline
regulated HA-tagged p73b (H24-p73b-22 HA-tagged) were
previously described (50) and were a generous gift from
Dr Xinbin Chen (University of Alabama). They were grown
in DME medium supplemented with 10% FBS, 2 mg/ml pur-
omycin, 250 mg/ml G418 and 5 mg/ml tetracycline. To induce
protein expression cells were plated without tetracycline,
washed three times with medium lacking tetracycline, and
24 h later were treated with N,N,N0,N0-tetrakis-(2-pyridyl-
methyl)ethylenediamine (TPEN) and/or metals as described
in Figure 1 for 2 h prior to lysis in buffer described below
in the puriﬁcation protocol.
For electrophoretic mobility shift assays (EMSAs) examin-
ing p53 DNA binding, we used afﬁnity puriﬁed monoclonal
p53 antibodies DO-1 and 421 and for p73, an afﬁnity puriﬁed
anti TAp73 N-terminal polyclonal antibody (TAp73N) (55)
and anti-p73 Ab-2 (ER15) (Calbiochem). Anti-HA
(Covance), anti-Flag (Sigma) and anti-His (Santa Cruz) anti-
bodies were used to detect the recombinant p53 and p73
proteins by western blotting.
Purification of p53 and p73
SF9 insect cells were infected with baculoviruses expressing
HA-tagged versions of p53 and p73. After 48 h, the cells
were collected and incubated for 30 min in lysis buffer
(50 mM Tris–HCl, pH 8.0, 150 mM NaCl, 1% NP-40,
0.1% aprotinin, 0.35 mM phenylmethylsulfonyl ﬂuoride,
1 mM DTT, 100 mM benzamidine, 300 mg/ml leupeptine,
10 mg/ml bacitracin and 100 mg/ml a-macroglobulin) on ice
and centrifuged to remove debris. The supernatant was incu-
bated with an anti-HA monoclonal antibody (12CA5) cross-
linked to Protein A Sepharose beads while rocking for 3 h
at 4 C. Beads (300 ml) were collected by centrifugation at
1400 g and washed twice with 10 ml buffer containing
20 mM Tris–HCl, pH 8.0, 100 mM NaCl, 1% NP-40, 10%
glycerol and 1 mM DTT, twice with 10 ml of the same buffer
lacking NP-40, followed by washing in 1 ml of a high salt
buffer (20 mM Tris–HCl, pH 8.5, 10% glycerol, 250 mM
NaCl and 1 mM DTT). p73 or p53 proteins were then eluted
at 30 C with buffer (20 mM Tris–HCl, pH 8.5, 10% glycerol,
500 mM NaCl and 1 mM DTT) containing 100 mg/ml HA
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CA). Consecutive fractions were taken every 2 min by
centrifugation. To determine preparation yield, the protein
was then incubated in Protein Sample (PS) buffer (ﬁnal
concentration: 10% glycerol, 0.7 M 2-mercaptoethanol, 4%
SDS, 167 mM Tris, pH 6.8, and 0.3 mg/ml Bromophenol
Blue) for 10 min at 100 C and analyzed by SDS–PAGE
and silver staining.
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p53 or p73 protein was preincubated for 10 min in 1· EMSA
buffer (12.5 mM Tris–HCl, pH 6.8, 25 mM KCl, 10%
glycerol, 0.05% Triton-X, 0.5 mg/ml BSA, 1 mM DTT
and 150 ng mutant p21 oligonucleotide) and then incubated
with 5 ng oligonucleotide, which was radioactively labeled
with [g-32P]ATP using T4 polynucleotide kinase, for another
20 min unless otherwise stated. The samples were run on
a 4% polyacrylamide gel at 200 V. The gel was transferred
to blotting paper, dried and exposed to KODAK ﬁlm.
For dissociation experiments, protein was incubated with
labeled oligonucleotide for 20 min. 50-fold excess of
competitor was then added for the indicated time and the
reaction mixture was loaded onto a running gel.
For experiments with extracts of H1299 cells, the same
buffers and conditions were used as above, except the
experiments were performed in the presence of 300 ng of
mutant p21 oligonucleotide.
The following oligonucleotides were used (boldface—p53-
binding site in which lower case signiﬁes deviation from
consensus sequence):
p21,5 0-AGCTAGTAGAGCGAACATGTCCcAACATG
TTgGCGTGCTGCAGC; p21,5 0-mut AGCTAGTAGAGC-
GAAtATaTCCcAAtATaTTgGCGTGCTGCAGC; GADD45,
AGCTAGTAGAGCGAACATGTCTAAGCATGCTgGC-
GTGCTGCAGC; MDM2, AGCTAGTAGAGCGGtCAAG-
TTgGGACAcGTCCGCGTGCTGCAGC; 14-3-3-sigma, AG-
CTAGTAGAGCtAGCATtagCCCAGACATGTCCGCGT-
GCTGCAGC; PIG3, AGCTAGTAGAGCcAGCTTGCCC-
AccCATGCTCGCGTGCTGCAGC; KILLER/DR5, AGCT-
AGTAGAGCGGGCATGTCCGGGCAAGaCgGCGTGC-
TGCAGC; PUMA, AGCTAGTAGAGCctGCAAGTCCtG-
ACTTGTCCGCGTGCTGCAGC; PCNA, AGCTAGTAGA-
GCGAACA AGTCCGGGCATaTgTGCGTGCTGCAGC;
PPC, AGCTAGTAGAGCtGGCATGTCCcGACTTGTTa-
GCGTGCTGCAGC; PPN(s), AGCTAGTAGAGCtGGCAT-
GCTTcGGCTTGCTaGCGTGCTGCAGC; PPN(o), AGC-
TAGTAGAGCtGGCATGaggcGTCTTGATaGCGTGCTG-
CAGC.
Cloning and mutagenesis
Mutant p53 C242S and p73b C262S were made using the
Stratagene Quickchange mutagenesis kit and the correspond-
ing baculoviruses were generated using the BactoBac kit
(Invitrogen).
Site-specific protein modification
mPEG-MAL 5000 was purchased from Nektar Therapeutics.
A stock solution (20 mM) was prepared in water. For
modiﬁcation, puriﬁed protein (20 ng) was preincubated with
50 mM EDTA for 30 min on ice and then further incubated
with 1 mM mPEG-MAL in 20 mM Tris–HCl (pH 6.8) on ice
for 1 h.
Luciferase assay
The PPC and PPN(s) binding sites were cloned into the
pGL3-OFLuc vector upstream of a minimal c-fos promoter
at position 58 (vector kindly provided by R. Prywes). These
constructs were then co-transfected with pcDNA3 plasmids
expressing Flag-tagged p53 or p73b (gift of T. Tanaka) into
H1299 cells using Lipofectamine 2000 transfection reagent
(Invitrogen) and the luciferase activity was assessed using
the manufacturer’s protocol (Promega). Renilla luciferase
was used as transfection control.
DNA-binding immunoassay
HA-p53, HA-p73b, His-p53C242S and His-p73b262S bac-
ulovirus infected or uninfected SF9 cells were lysed as
described above, and incubated for 2 h at 4 C with anti-HA
antibody (MAb 12CA5) cross-linked Protein A–Sepharose
or nickel-NTA Agarose beads as appropriate. The matrices
were washed three times with lysis buffer, and then incubated
for 20 min with g-
32P-labeled p21 oligonucleotide, as
described for EMSA above. They were then washed three
times with EMSA buffer and the p21 oligonucleotide bound
was measured in a LKB Wallace liquid scintillation counter.
RESULTS
Purified p53 and p73b are differentially affected by the
zinc chelator EDTA
We puriﬁed baculovirally expressed HA-tagged versions of
p53 and p73b from SF9 cells and analyzed their in vitro
DNA binding by EMSA. Initial puriﬁcations of these two
proteins were performed using a protocol previously
described for p53 in this laboratory using buffers which con-
tain 1 mM EDTA (56). These protocols yielded active p53
but inactive p73b (data not shown). As both proteins share
homologous zinc-coordinating residues within their DNA-
binding domains, we postulated that DNA binding of p73b
Figure 1. p73b–DNA binding is more affected by zinc chelation than that of p53. (A and B) Purified p53 and p73b can bind DNA with similar affinity.
Baculovirally expressed HA-tagged p53 and p73b were affinity purified in the absence of EDTA using 12CA5 crosslinked beads, fractions 1–7 were eluted with
HA peptide as described in Methods and aliquots were subjected to SDS–PAGE and silver staining using 50, 100, 200 and 500 ng BSA as a standard protein (A).
Migration of molecular weight standard proteins is indicated at left. The red line at left indicates the 63 kDa protein weight marker, the two lines below it indicate
49 and 37 kDa markers respectively, and the line above is the 81 kDa marker. DNA binding of HA-p73b (lanes 1–7) and p53 (lanes 8–14) proteins (10 ng) to an
oligonucleotide containing the p21 50 p53-binding site (5 ng) was measured using EMSA (B). (C) Zinc, cobalt, but not copper reverse the effect of EDTA on
p73b–DNA binding. HA-tagged p73b was purified with buffers containing either no metals or EDTA, or EDTA (1 mM), or EDTA with zinc (both 1 mM), EDTA
with copper (both 1 mM), or EDTA with cobalt (both 1 mM) as in A. DNA binding to a p21 oligonucleotide was visualized by EMSA as in (B). (D) p73b–DNA
binding activity is inhibited at much lower concentrations of EDTA than that of p53. HA-tagged p53 and p73b (purified in the absence of zinc or chelator) were
preincubated for 30 min with increasing concentrations of EDTA [12.5, 25, 50 and 100 mM (pH 6.8)] and DNA binding of p53 (lanes 1–5) and p73b (lanes 6–10)
to a p21 oligonucleotide was assessed by EMSA as in (B). Graph shows quantification of results by phosphorimaging. The results are plotted as percentage of
control incubated in the absence of EDTA (lanes 1 and 6). (E) Zinc reverses the TPEN-induced inhibition of p73b–DNA binding in vivo. HA-tagged p73b
expression was induced in H1299 cells by removal of tetracycline. After 24 h, cells were treated for 2 h with 40 mM TPEN (lane 2), 160 mM ZnCl2 (lane 3),
160 mM CuCl2, or a combination of TPEN and ZnCl2 (lane 4) or TPEN and CuCl2 (lane 6) at the same concentrations for 2 h and then lysed. An EMSA
was performed using whole cell extracts with a p21 50 binding site containing oligonucleotide (upper panel). Quantification of the EMSA DNA-binding results
is in the middle panel with DNA-binding normalized for protein expression and plotted as percent of untreated control. The p73b protein expression levels
(detected by HA antibody) in the corresponding cultures treated as described above are in the bottom panel.
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the absence of EDTA. This did yield p73b protein that was
able to bind DNA (Figure 1). The quantiﬁcation by silver
staining of consecutive fractions of proteins from a represen-
tative puriﬁcation using BSA as standard is shown in
Figure 1A and their DNA binding, as assessed by performing
an EMSA, using a radioactively labeled oligonucleotide con-
taining the p21 50 p53 binding site/response element (RE) is
shown in Figure 1B. While there was some variation in DNA
binding between different preparations of the two proteins,
overall there were no consistent differences in steady-state
DNA binding between p53 and p73b.
To conﬁrm that the observed effect of EDTA on p73b was
due to the metal chelating properties of EDTA, we added zinc,
copper and cobalt in equimolar ratios to EDTA to the puriﬁca-
tion buffers (all at 1 mM). The addition of zinc and (to a lesser
extent) cobalt, but not copper, rescued p73b DNA binding,
presumably by saturation of EDTA (Figure 1C).
Figure 2. Differential roles of cysteine residues in core domains of p53 and p73. (A) The conformation of p73b is more significantly affected by zinc chelation
than that of p53. Purified HA-tagged p53 and p73b (20 ng) proteins were incubated with MAL-PEG (1 mM) in the presence or absence of 50 mM EDTA as
indicated. Proteins were visualized by SDS–PAGE. More slowly migrating p53 and p73 species arising from MAL-PEG tagging are indicated (MAL-PEG/p53
and MAL-PEG/p73). Migration of molecular weight standard proteins is indicated in center lane. The red line indicates the 63 kDa protein weight marker, the
two below it are 49 and 37 and the two above are 81 and 115 kDa respectively (B–D). A zinc-coordinating mutant of p73b cannot bind DNA. (B) A sequence
alignment of the zinc-coordinating regions of p53 and p73. The zinc-coordinating cysteines and histidine are highlighted in red and the substitution made in the
p53C242S and p73bC262S is highlighted in blue. (C) No difference is observed in the DNA binding of wild-type p53 and p73b using an immunobinding assay.
Wild-type HA-tagged p53 and p73b proteins were baculovirally expressed in SF9 cells at 23 C. Upper panel: The DNA-binding activity of the two proteins
immobilized on 12CA5 crosslinked to Protein A Sepharose was assessed by a DNA immunobinding assay, with lysate from uninfected cells used as a control
(mock). The immobilized protein was incubated with 5 ng of a g-
32P-labeled p21 oligonucleotide, the matrix was washed, and the amount of bound DNA
assessed by scintillation counting. Background levels of radioactivity of matrix that was incubated with oligonucleotide alone were subtracted from the mock and
HA-p53 and HA-p73b infected samples, and the fold increase in radioactivity over the mock samples was plotted. Lower panel: The proteins immobilized on
beads were heated in PSB and subjected to SDS–PAGE followed by immunoblotting with anti-HA antibody. (D) p53(C242S) but not p73b(C262S) retains DNA-
binding activity. His-tagged p53(C242S) and p73b(C262S) mutant proteins were baculovirally expressed in SF9 cells at 23 C. Upper panel: The DNA-binding
activity of the two proteins immobilized on Ni-T-Agarose matrix was assessed by a DNA immunobinding assay using a p21 oligonucleotide as in (C). Lower
panel: The amount of protein present on the matrix was visualized by immunoblotting with anti-His antibody.
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DNA binding, we incubated the two proteins (puriﬁed without
chelator) with increasing amounts of EDTA (0, 12.5, 25,
50 and 100 mM). An almost 4-fold higher amount of
EDTA was needed to disrupt p53 binding to a p21 50 RE-
containing oligonucleotide as compared to p73b (Figure 1D).
To determine if zinc chelation has an effect on p73 DNA
binding in vivo, we followed a protocol previously described
for p53 (29), using the intracellular zinc chelator, TPEN,
a membrane permeable metal chelator with a high speciﬁcity
for zinc (57). Ectopic p73b expression was induced in H1299
cells (50) which were then treated either with TPEN alone, or
in the presence of zinc or copper. The cells were lysed after
2 h, and p73 DNA binding was measured by EMSA in cell
extracts (Figure 1E). The DNA-binding activity of p73 was
signiﬁcantly impaired in the presence of TPEN (compare
lanes 1 and 2), and, as seen with puriﬁed protein, this inhibi-
tion was completely reversed by simultaneous addition of
zinc (compare lanes 3 and 4) but only partially reversed by
addition of copper (lanes 5 and 6).
Altered roles and exposure of cysteine residues in
p53 and p73 core domains
A previous report has shown that treatment of cells with the
metal chelator TPEN disrupts p53 conformation as assessed
by immunoprecipitating with an antibody MAb 240 (29)
that recognizes p53 in a partially unfolded mutant conforma-
tion (26,58). Since p73b DNA binding was more affected by
EDTA than that of p53, we hypothesized that the structure of
p73b is more affected by chelation of its zinc atom than is
that of p53 under our conditions. All p53 cysteine residues
and all but one (located at the extreme C-terminus) p73b cys-
teine residues are located in their respective core domains.
Since no conformation-speciﬁc antibody currently exists for
p73b, we decided to assess differential exposure of cysteines
in the two proteins by tagging the thiol groups of the cys-
teines with maleimide-polyethylene glycol (MAL-PEG)
(59,60). If the cysteines are buried within the protein,
MAL-PEG should not be able to access them. However, if
the protein conformation is altered and these residues are
exposed following EDTA chelation, they will be accessible
to MAL-PEG and tagged. Furthermore, since the bond formed
between a thiol and a maleimide is a disulﬁde bond, the
tagging can be assessed by denaturing SDS–PAGE to observe
the appearance of slower-migrating species.
HA-tagged p53 and p73b were either untreated or treated
with 50 mM EDTA for 20 min and then incubated for 1 h
with 1 mM MAL-PEG on ice. After denaturation at 100 C
in protein sample buffer, SDS–PAGE was performed, and
the proteins were visualized by immunoblotting with anti-
HA antibody. Slower-migrating species of both p53 and
p73b were present following MAL-PEG tagging without
EDTA, indicating that some core cysteines in each protein
are accessible to this reagent (Figure 2A). Strikingly, while
there were only minor additional species detected when p53
was pretreated with EDTA, much more prominent slower-
migrating species were present when p73b was preincubated
with EDTA before MAL-PEG. These data therefore indicate
that zinc chelation by EDTA more profoundly changes the
conformation of p73b than of p53.
Since the structure of p53, as measured by cysteine
exposure, did not seem to be grossly disturbed by zinc chela-
tion in vitro, we hypothesized that under some conditions p53
but not p73b should be able to bind DNA in the absence of
a key residue required for coordinating zinc. In fact, it
was previously shown that mutating zinc-coordinating
cysteines of murine p53 signiﬁcantly decreases, but does
not completely abrogate the DNA-binding activity of the
protein when it is expressed at 20 C (61). We generated
baculoviruses expressing His-tagged versions of the zinc-
coordinating mutant human p53(C242S) and the equivalent
residue in p73b(C262S) (Figure 2B). These respective sites
were chosen because in p53 this mutation had been shown
to have the least effect on DNA binding (61). Note that
when we used MAL-PEG to assess EDTA-induced unfolding,
the two mutant proteins did not show a change in the appear-
ance of tagged species, suggesting weak zinc coordination
activity(datanotshown).Sincethesemutantsweremoreeasily
denatured during the process of puriﬁcation from insect cells,
weemployedaDNA-bindingimmunoassayinwhichlysatesof
insect cells infected with baculoviruses expressing wild-type
or mutant p53 or p73b proteins were immunoprecipitated
with the appropriate antibody immediately followed by
incubation with a radioactively labeled p21 oligonucleotide.
Wild-type versions of both proteins bound approximately
similar amounts of the p21 oligonucleotide (Figure 2C).
While the p53(C242S) mutant has reduced DNA-binding
activity compared to wild-type protein ( 20-fold reduction,
data not shown) it did retain some DNA-binding activity
( 3-fold over background) when incubated with a p21-RE-
containing oligonucleotide. In contrast, the p73b(C262S)
mutant exhibited minimal DNA-binding activity (1.5-fold
over background, Figure 2D). This suggested that DNA
binding of p73b is more signiﬁcantly affected by the inability
to coordinate zinc than that of p53. Since wild-type p53 and
p73b proteins exhibit a roughly equivalent DNA-binding
activity on a per mole basis, we conclude that the difference
in DNA binding of the mutants is due to the differential effect
of the cysteine mutation.
DNA binding protects p73 from EDTA chelation
To further elucidate these differences, we compared the
effects of EDTA on p53 and p73b after they were bound to
DNA. We used oligonucleotides containing p53 binding
sites from the p21 and KILLER/DR5 promoters. Puriﬁed
HA-tagged p53 and p73b were either incubated with EDTA
after which DNA was added, or preincubated with DNA
and then exposed to EDTA. DNA binding was then assessed
by EMSA (Figure 3). In agreement with our previous results
(see Figure 1D) preincubating with EDTA signiﬁcantly
reduced the DNA-binding activity of both proteins although
different concentrations of EDTA were used in each case to
assure that some DNA binding was still detectable (40 mM
for p53, 12.5 mM for p73b). Using the p21 oligonucleotide,
preincubating p53 with DNA only modestly reversed
the inhibition by EDTA ( 2-fold) while p73b DNA binding
was dramatically rescued after such preincubation
( 16-fold). Similar effects were shown over a range of
EDTA concentrations and overall p73b dissociation rate
was not affected under these conditions (data not shown).
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DR5 site ( 5-fold) was signiﬁcantly less than to the p21 site.
Taken together, these data suggest a stronger need for the
zinc atom for the DNA-binding active conformation of p73b
than p53, which supports our speculation of differential fold-
ing of their respective DNA-binding domains.
p53 and p73 bind DNA in a sequence-specific manner
but exhibit different sequence-specific stability
The differential protection of p73b on the p21 and KILLER/
DR5 REs (Figure 2B), the putative difference in the folding
of DNA-binding domains of p53 and p73b, as well as previ-
ously reported effects of mutation on p53 sequence speciﬁcity
(62,63), led us to further investigate differences in DNA
binding between the two proteins. It is well documented
that a C-terminal speciﬁc p53 antibody (MAb 421) increases
the binding of p53 to short oligonucleotides containing p53-
binding sites (33). We were ﬁrst interested in whether an
antibody that interacts with the C-terminus of p73b might
have a similar stimulatory effect. To test this, p53 and p73b
were each incubated with antibodies that recognize their
respective C- and N-termini (MAbs 421 and DO-1 for p53
and Mab ER15 and PAb TAp73N for p73) and EMSAs
were performed comparing binding of the proteins to
oligonucleotides containing either p21 or PIG3 p53 binding
sites (Figure 4A). As predicted, while the N-terminal anti-
body MAb DO-1 did not affect p53 binding to either site,
the C-terminal MAb 421 markedly increased p53 DNA bind-
ing under the assay conditions used. In contrast, neither the
TAp73 N-terminal polyclonal antibody (TAp73N) nor
the C-terminal antibody (ER15) affected p73b DNA binding
to the p21 oligonucleotide, although there was a modest
increase in binding to the PIG3 oligonucleotide with both
antibodies. Nevertheless, the effects with the p53 C-terminal
antibody were much more signiﬁcant with both sites, indicat-
ing a difference in the function of the C-terminus between the
two proteins. This is consistent with the fact that there is no
region in p73 isoforms that resembles the highly basic p53
C-terminus.
To conﬁrm that sequence-speciﬁc DNA binding was being
observed, a competitor curve was performed, using unlabeled
oligonucleotides containing either the wild-type 50 RE p53-
binding site in p21 (p21wt) or a sequence in which key
nucleotides in this site were mutated (p21mut) to compete
for binding to a radioactively labeled oligonucleotide contain-
ing the p21 50 RE. As expected, both p53 and p73b DNA
binding was competed by p21wt but not p21mut oligonu-
cleotides. Surprisingly, however, p73b was dramatically
more stable on the p21 DNA site than was p53 (Figure 4B).
To determine if the lower dissociation rate of p73b is
speciﬁc to the p21 site, competitor EMSAs were performed
using oligonucleotides containing p53 binding sites from
several p53 target genes including p21, GADD45, MDM2,
14-3-3-sigma, PCNA, PIG3, KILLER/DR5 and PUMA.W e
used sequences from both pro-apoptotic and non-apoptotic
target genes, since some difference in transactivation by
p53 have been reported for these two classes of genes. Inter-
estingly, p53 had roughly similar dissociation rates from all
promoters used (Figure 4C), while p73b exhibited dramati-
cally lower dissociation rates speciﬁcally from two of the
sites tested: p21 and PUMA (Figure 4D). Note that although
p73a binds more weakly to DNA than p73b (45) we obtained
essentially similar results in that puriﬁed p73a protein
dissociated more slowly from the p21 than the PIG3 binding
site-containing oligonucleotides (data not shown). Moreover,
puriﬁed DNp63b protein was also more stably associated with
the p21 than the KILLER/DR5 site (Supplementary Figure 1).
Five bases in the p53 consensus sequence confer stable
binding exclusively on p73b
Comparing the sequences of the p21 and PUMA binding sites
revealed that they share ﬁve bases that are not together pre-
sent in any of the other p53 sites examined (Figure 5A).
In order to determine if these bases are necessary for the
decreased dissociation rate, we designed three oligonu-
cleotides that each conform generally to the p53 consensus
site but in which either the ﬁve bases common to p21
and PUMA were present, with the rest scrambled so as to
still conform to the p53 consensus site (p21-PUMA consen-
sus; PPC) or in which these ﬁve bases were changed either
to the same [purine ! purine; PPN(s)] or the opposite
[i.e. purine ! pyrimidine, PPN(o)] base. PPN(s) conforms
to the general consensus binding sequence to the same extent
as PPC, while the PPN(o) site deviates from consensus by
another ﬁve bases. The sequences of these sites are shown
in Figure 5B. When a competitor EMSA was then performed
with these oligonucleotides, there were no signiﬁcant differ-
ences in the dissociation rates of p53 from either of the above
artiﬁcial sites, which were similar to its dissociation from the
p21 site. Importantly, the dissociation of p73b was markedly
increased from the PPN as compared to the PPC sequence,
which approximated that of the PUMA and p21 binding
sequences. This shows that the ﬁve-base sub-sequence that
Figure 3. DNA prebinding protects p73b but not p53 from treatment with
EDTA. Purified HA-tagged p53 (lanes 1–8) and p73b (lanes 9–16) proteins
(10 ng) were incubated with EDTA (40 mM for p53 and 12.5 mM for p73) for
20 min and then oligonucleotides (p21 or KILLER/DR5 as indicated) were
added (lanes 1, 2, 5, 6, 9, 10, 13 and 14) for 20 min. Alternately p73b and p53
were incubated first with oligonucleotides for 20 min followed by addition of
EDTA at the same respective concentrations and incubation for another
20 min (lanes 3, 4, 7, 8, 11, 12, 15 and 16). DNA binding was quantified
by phosphorimaging, and the results plotted as percentage-binding retained
in each EDTA treated sample versus its untreated control.
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reduced dissociation of p73b. It is also interesting to note
that while the dissociation rate of p53 from PPC, PPN(s) or
PPN(o) did not vary, its steady-state binding to PPC was
greater than to PPN(s), and binding was even more reduced
to the PPN(o) sequence. This result correlates well with
results of transactivation by p53 in vivo (see below).
Deletion of the C-terminus allows p53 to discriminate
between PPC and PPN sites
As mentioned previously, p53 has a second sequence-non-
speciﬁc DNA-binding domain in its C-terminus that can
linearly diffuse and dissociate from ends of DNA (31).
Furthermore, it has been shown that the dissociation rate of
the C-terminus is up to 1000-fold higher than that of the
core DNA-binding domain (64). Based on this, we hypothe-
sized that the difference between p53 and p73b could be due
to the activity of the C-terminus, which might increase the
dissociation rate under the conditions of the assay in which
relatively short oligonucleotides (44 bp) were tested. If this
were the case, the C-terminus would mask any differences
in the ability of the core domain to dissociate from its binding
sites in DNA. To test this, we used a version of p53 protein in
which the C-terminal 30 amino acids have been deleted (HA-
tagged p53D30), rendering the protein unable to diffuse lin-
early along DNA (31). Indeed, when a similar analysis was
performed, p53D30 exhibited much lower dissociation from
the PPC versus the PPN site-containing oligonucleotides
(Figure 6). Thus, the core DNA-binding domains of p73b
and p53 are similar in their relative dissociations from the
PPC and the PPN sites in vitro. Furthermore, the p53 C-
terminus can overcome the slower dissociation from these
sites, presumably through its sliding activity and rapid disso-
ciation from the oligonucleotide ends.
PPC and PPN minimal promoters are differentially
transactivated by p53 and p73b
To explore the difference between sites that do or do not
contain the ﬁve-base p21-PUMA consensus sub-sequence in
the context of a cell, we used a luciferase reporter assay to
investigate the contribution of different p53-binding sites to
the abilities of p53 and p73b to activate transcription.
pGL3-OFLuc vectors containing the PPC and PPN(s) binding
sites were co-transfected into H1299 cells along with Flag-
tagged versions of p53 and p73b (Figure 7). Both p53 and
p73b transactivated the PPC promoter to a greater extent
Figure 4. p73b but not p53 dissociates very slowly from p21 and PUMA-binding sites. (A) EMSAs with HA-tagged p73b (lanes 1–6) and p53 (lanes 7–12)
proteins (10 ng) were performed in which DNA–protein mixtures were either untreated (lanes 1, 4, 7 and 10) or treated with antibodies to the C- (MAb ER15,
lanes 2 and 5) and N- (TAp73N, lanes 3 and 6) termini of p73b or C- (MAb 421, lanes 8 and 11) and N- (MAb DO-1, lanes 9 and 12) termini of p53. The p21 50
(lanes 1–3 and 7–9) and PIG3 (lanes 4–6 and 10–12)-binding site containing oligonucleotides were used. (B) The sequence-specificity of HA-tagged p73b (lanes
1–7) and p53 (lanes 8–14) (10 ng)–DNA binding was assessed by performing EMSAs in which binding to a g-
32P-labeled oligonucleotide containing the p21 50
binding site sequence was competed by adding excess unlabeled oligonucleotides with wild-type p21-binding site sequence (p21wt) or mutated p21 50 binding
site sequence (p21mut) at increasing fold molar excess (25, 50 and 100). (C and D) Competitor EMSAs were performed with HA-tagged p53 and p73b proteins
using p53-binding sites from non-apoptotic (p21, GADD45, MDM2, 14-3-3-sigma and PCNA) and pro-apoptotic (PIG3, KILLER/DR5 and PUMA) genes. In each
case a 50-fold excess of the corresponding unlabeled oligonucleotide was used as competitor. The results are plotted as amount of binding retained as percent of
control.
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pronounced for p53 (4- and 15-fold) than p73b (2-fold).
This result suggested that the ﬁve-base sub-sequence in the
binding site plays a role in the level of transactivation. The
stronger effect on p53 was surprising in that from the
DNA-binding assays one would have predicted the opposite
result. This ﬁnding is consistent, however, with the fact
that, as shown in Figure 5C, there was a much bigger differ-
ence in net p53 binding to the PPC versus PPN sites than
observed with p73b. Furthermore, p53D30 exhibited a trans-
activation pattern similar to that of full-length p53 (data
not shown) further supporting core DNA-binding domain
sequence speciﬁcity. Taken together, there is a good corre-
spondence between the in vitro dissociation data and
in vivo transactivation results for both p53 and p73b. Further-
more, the p53 C-terminus plays a critical role in vitro but not
in vivo in this sequence selectivity.
DISCUSSION
Our studies have revealed several differences between
puriﬁed preparations of p53 and p73b proteins in their inter-
action with DNA. First, p73b is apparently signiﬁcantly more
dependent on zinc coordination for binding DNA than is p53
based on its relatively greater sensitivity to EDTA, reactivity
with MAL-PEG and virtually complete loss of activity caused
by mutation of a zinc-coordinating cysteine. Second, DNA
binding offers a much greater protection to p73b than p53
from zinc chelation. Finally, while full-length p53 and p73b
proteins differ in their preference for binding to p53-binding
sites with a speciﬁc sub-sequence that we have identiﬁed, the
core sequence-speciﬁc DNA-binding domains of the two
proteins exhibit similar sequence preference both in vitro
and in vivo.
Our data suggest that there is a difference in the structure
of the DNA-binding domains of p53 and p73, especially
with respect to their zinc-coordinating residues. Our initial
experiments revealed a more signiﬁcant effect of the metal
chelator EDTA on p73b than p53, an effect reversed by
Figure 5. A five-base sub-sequence in the canonical p53-binding site is
required for the lower dissociation rate of p73b.( A) Sequence alignment of
the binding sites used in Figure 4C and D reveal five conserved bases in the
p21- and PUMA-binding sites. The five bases conserved between p21 and
PUMA are in red, the bases that deviate from this consensus in the other six
binding sites are in black. Bases that deviate from p53 consensus are in lower
case. (B)Ap21-PUMA consensus (PPC) and two non-consensus sequences
(PPNs) were generated. The PPC sequence is a combination of p21 and
PUMA sequence, the PPN(s) is the same sequence with the five common p21/
PUMA nucleotides mutated purine to purine and pyrimidine to pyrimidine,
and the PPN(o) has the 5 nt mutated purine to partner pyrimidine and vice
versa. Invariable CWWG is in bold. Changed bases are in red bold. (C) The
dissociation rate of p73b is increased to that of p53 by changing five bases in
the p21-PUMA consensus binding site. Competitor EMSAs with HA-tagged
p53 (lanes 1–9) and p73b (lanes 10–18) proteins were performed as in Figure
4 using the PPC and two PPN sequences. The proteins were preincubated
with radioactively labeled oligonucleotide, followed by a 0.5, 1 and 5 min
incubation with a 50-fold excess of self competitor. DNA binding was
quantified by phosphorimaging and the values plotted as percent of control.
Note that reaction mixtures were loaded onto a running gel at different time
points after the start of the experiment.
Figure 6. The DNA-binding domain of p53 exhibits similar sequence
selectivity as that of p73b. Baculovirally expressed, purified HA-tagged
p53D30 protein (5 ng) was preincubated with radioactively labeled PPC
or PPN oligonucleotides as indicated, followed by a 0.5, 1, 5 and 10 min
incubation with a 50-fold excess of unlabeled corresponding oligonucleotide
as competitor. Reaction mixtures were loaded onto a running gel at different
time points after the start of the experiment. DNA binding to PPC or PPN
sites as indicated was quantified by phosphorimaging and the values plotted
as percent of control.
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this observation by showing that, in contrast to p53, the
structure of the p73b DNA-binding domain is signiﬁcantly
changed after zinc chelation by EDTA. More cysteines
become accessible to maleimide tagging, indicating that the
structure takes on an unfolded conformation in the absence
of the zinc atom. This is not seen with p53.
Recent publications describe the interaction of p53 dimers
across DNA (15,16). Data from crystal structures of p53 core
domain bound to DNA suggest that several p53 residues in
dimers bound to the same half-site interact with each other
forming an interface that further stabilizes the protein on
DNA. Of these, neither the two charged residues (His178
and Arg181) nor the one hydrophobic residue (Met243) are
conserved in p73, where they are replaced by non-charged
and non-hydrophobic residues (Asn196, Leu201 and Val263).
This might provide a further explanation for our observation
of differential zinc dependence of p53 and p73b such that if
p53 has an additional means to stabilize its interaction with
DNA, structural perturbations are likely to affect p53 DNA
binding to a lesser extent than that of p73. Our data showed
that a mutation of a zinc-coordinating residue in p53 and
p73b leads to an inactive protein in the case of p73b but
not p53 and is consistent with p73b DNA binding being
more affected by zinc chelation. In the absence of zinc, the
DNA-binding domain of p73 may undergo a greater confor-
mational change not compensated for by dimer interaction
across the DNA, thereby resulting in a complete loss of
DNA binding.
DNA protection from EDTA demonstrates another possi-
ble structural difference between p53 and p73b. It is possible
that p73b is protected from zinc chelation by being prebound
to DNA because the zinc-coordinating residues of p73 are
relatively more buried within the protein when it is bound
to oligonucleotide. It was reported that Tyr236 and Thr253
in the DNA-binding domain of p53 destabilize the structure
and these residues are not conserved in p73 (65). These
unpaired hydrogen bond donors/acceptors may allow for
greater solvent exposure of the zinc-coordinating region of
p53 which could in turn explain why p53 is not well protected
from EDTA by DNA. We speculate that in the case of p73,
this region is not exposed to solvent when the protein is
bound to DNA.
Our ﬁndings of differential sensitivity of p73b and p53 to
EDTA might be important when using chelating chemother-
apy in tumors [e.g. reduction of copper levels to inhibit
angiogenesis (66)] that lack functional p53 but have wild-
type p73. In this scenario, the chemotherapeutic drug might
render p73 non-functional, and potentially cause the cell to
be even less capable of undergoing apoptosis.
These differences in the DNA-binding domain structure of
p53 and p73 prompted us to examine whether the two pro-
teins might display dissimilarities in preferred DNA binding
sites. Several previous studies have examined DNA binding
by p73 proteins (1,41,42,45,67–70), although currently a sin-
gle report directly compares in vitro DNA binding of puriﬁed
p53 and p73 proteins, and demonstrates that baculovirally
expressed Flag-tagged p53 and p73 exhibit similar sequence-
speciﬁc afﬁnity for a consensus binding site as assessed by
EMSA (67). However, the presence of both p53 and p73-
speciﬁc promoters in the genome (53), along with the recent
discovery of a novel p73/p63 but not p53 responsive
promoter, consisting of a canonical p53 RE and a second,
GC-rich RE (71) raised the possibility of differences in
DNA sequence selectivity between p53 and p73. Indeed,
our initial results suggested this to be the case when we
found that p73b dissociates much more slowly from p21
and PUMA binding sites, a phenomenon not observed with
full-length p53. It was therefore unexpected that deletion of
the p53 C-terminus produces a protein which behaves
similarly to p73b in its discrimination of sequences from
which it dissociates. That similar results were obtained for
the third family member, p63 shows that this sequence
discrimination is a property of the DNA-binding domains
of all three p53 family members.
In fact, our conclusion that the core domains of p53 and
p73b are similar in slowed dissociation from sites with a
unique sub-sequence are consistent with the observation
that in the cell, both p53 and p73b exhibit relatively higher
transactivation from a minimal promoter containing this
sub-sequence. While both p53 and p73b transactivate PPC
and PPN site containing reporters in transfection assays to
a different extent, the difference is more pronounced in
the case of p53. Although this is difﬁcult to explain at present
it could be due to some structural difference between
the DNA-binding domains of the two proteins, though
we cannot rule that they recruit different transcriptional co-
factors.
That p73b binding resembles that of p53D30 but not
full-length p53 further supports the ﬁnding that p73 isoforms
Figure 7. Both p53 and p73b can discriminate between PPC and PPN sites
in vivo.( A) p53 and p73b transactivate a PPN reporter to a lower extent than
a PPC reporter. Plasmids (8 and 40 pg, represented as 1X and 5X,
respectively) expressing either Flag-tagged p53 or p73b proteins were
cotransfected with pGL3-OF Luc reporter vectors containing either PPC or
PPN(s)-binding sites as indicated along with a pRL (Renilla) control vector
into H1299 cells. The cells were lysed, 24 h after transfection, and luciferase
activity measured. The luciferase activity was normalized to Renilla and the
induction was plotted versus the appropriate pGL3 reporter alone. A
representative experiment performed in triplicate is presented. (B) Constructs
expressing Flag- tagged p53 and p73b proteins were transfected into H1299
cells (8 and 40 ng, represented as ·1 and ·5, respectively) as in (A) and
proteins were detected by immunoblotting with an anti-Flag antibody.
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similar to that located in the C-terminus of p53. Interestingly,
when a four-base spacer was inserted between the two PPC
half-sites, the dissociation rate of p53D30 increased to that
observed on a PPN site, suggesting the importance of spacing
as well as sequence (data not shown).
There is some evidence suggesting that p21 and PUMA are
stronger transactivation sites and are sites which can be
uniquely transactivated by certain p53 mutants. For example,
there is greater p53 binding, as seen by ChIP, to the p21 and
PUMA than PIG3 and AIP1 promoters (19) and a greater
histone acetylation at the p21 and PUMA than MDM2
promoters (72). Furthermore, several p53 mutants have
been shown to transactivate the p21 promoter, but not the
Bax and PIG3 promoters in yeast (73). In addition, Nicholls
et al. (74) have shown that wild-type/hotspot mutant hetero-
tetramers show almost wild-type activity on p21 out of all
binding sites used except for an artiﬁcial full consensus
sequence (PUMA was not used in their experiment). The sub-
sequence we have here described could confer more stable
binding, thus allowing even the p53 mutants to retain some
DNA binding on p21 and PUMA promoters.
Recent crystal structure of p53 core domains bound to
different oligonucleotide sequences from Kitayner et al.
(15) suggests that an A preceding and a T following the
invariable CWWG core of the binding site (which is one
feature of the sub-sequence we identiﬁed) allows Lys120,
Ala276 and Arg280 to mediate a stronger p53/DNA interac-
tion. These residues are conserved in p73 (Lys138, Ala322
and Arg325) further supporting the preferential interaction
with some DNA-binding sites by p53 and p73b. These data
in conjunction with our ﬁndings suggest a conservation of
RE selectivity as well as DNA-interacting residues between
p53 and p73. Hopefully the differences and similarities
between p53 and p73 that we have observed can be eluci-
dated when the atomic structure of the p73 core domain is
solved.
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